Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. - Wikidata - awgldk - TriplyDB

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

http://www.wikidata.org/entity/Q34540403

about

Current perspectives on cardiovascular outcome trials in diabetes SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.Understanding and overcoming metformin gastrointestinal intolerance.Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk The impact of antihypertensives on kidney disease.Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes.Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.Advances in Clinical Cardiology 2016: A Summary of the Key Clinical Trials.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SB Macrophage functions in lean and obese adipose tissue.Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry.Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.Blood pressure control in type 2 diabetic patients.Looking to a future of improved diabetes management: interview with Professor Steve Bain.Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.The effect of SGLT2 inhibitors on cardiovascular events and renal function.Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials.The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes.Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.Review article: new treatments in non-alcoholic fatty liver disease.Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball.Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials.The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease.Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.Pharmacological Interventions against Obesity: Current Status and Future Directions.A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.

P2860

Q28066006-6E363997-FB00-4758-A176-D1A70CCA2EF0 Q30238791-78B01CE4-2779-4F6D-81CB-EE4F44AC0E29 Q30240030-33F47433-7C6F-4251-A5AA-FD841C93261A Q31167862-EC3A7ADA-FFAF-4096-92D6-65527C3492D7 Q33601429-B8C97084-917B-4600-AC84-0BC02C090F7D Q33632021-6978AEC2-87F7-48D6-B46F-F25CCD09AB41 Q33732627-C933DA22-4361-4328-AF05-81F0D7AD4AAE Q33775785-864D78DA-0B41-45A4-8470-3DAF1325759E Q33871304-2F06C16D-1A04-4DD9-A5F1-72A7ABBF7ED2 Q33887783-E13887B9-396D-42FD-9D35-7EF6F706D0F1 Q33890811-DACFC62E-E0B6-4B62-8FE4-B4C46BF4D512 Q33908782-893EAAAA-0874-4EEB-82DC-B252A273035D Q36412774-D47707C6-38E7-4035-8C8A-6589059D83FC Q37466439-D00F6B9C-572E-4CCE-8400-D6BFF2D597F9 Q37562586-2578E466-445E-4213-9D5F-68D330A361D2 Q37566950-80E9BC11-EC9C-4ECB-81A3-A9B9BD5DCBA1 Q37591845-ECCB8269-157E-4D1B-B1B2-84A91BE3BDED Q37611715-73548B8B-9A01-4D1C-B046-4A47698A8173 Q37620904-82C55F7D-3152-451C-8D47-ED787956105A Q37676824-A3A1DE8E-D4AF-4642-AC4D-0EC0B0506381 Q37696496-9580CBD8-A21A-4FB3-AEF3-B7CFE60FAFF3 Q38378906-611901C9-68C6-44A7-90C4-B60AB5301269 Q38614488-47BE04F5-487C-4EAD-A746-3528A97E7275 Q38627117-F4438154-4635-40C9-994C-3FE679BB663E Q38629197-DA4EA90B-44FD-4726-BFA1-7BA64E16642E Q38654698-7510E326-8D66-40AD-834A-79A6D7113C52 Q38658251-B080E382-49A3-4925-9972-917D04100876 Q38662690-7236D02F-E7D9-45D5-A483-DAE669C81331 Q38662765-F8BF60E7-B136-4F5E-AB26-4E5400F24F34 Q38665806-5A5A4FE7-3B7C-4C02-A987-047F60C51CEC Q38676310-5D5CC5D5-86C3-409D-914B-CC66818C5AB5 Q38679997-4618F66E-97B7-478B-B10D-5FD366BEEDEA Q38683079-08E52452-8162-48E1-8F01-C01AB7FFC24E Q38688345-E4A91A48-F603-4941-B4D5-CA5EA6885DE5 Q38692092-3F67A0C8-609C-481F-A0B5-3EDAD2D1DFEC Q38744831-832DEADE-CFB2-4FF9-9533-54CEAB05081F Q38778064-7E867006-225A-4AF4-8919-DE2DF1A90376 Q38786770-1F71750B-C90C-46E0-85EA-9674480B8A7E Q38802810-A13B5AB7-8200-484E-B470-01D1B01B9F13 Q38824034-059F8600-CF12-4768-887C-876FE5A1993C

P2860

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

http://www.wikidata.org/entity/Q34540403

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

@ast

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

@en

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

@nl

type

label

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

@ast

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

@en

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

@nl

prefLabel

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

@ast

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

@en

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

@nl

P1433

Q34540403-3E9A1799-EDAF-4DEF-92BC-AC8410AC98B5

P1476

Q34540403-071053CA-5C76-4E80-A509-DE4EE152654F

P2093

Q34540403-046D8DD7-5D70-47DA-ACC9-50A37978ADF3

Q34540403-1DD06E40-000A-406D-895D-B3E1CFCBD762

Q34540403-33C3604C-7F55-4F50-91FA-73147CFD60CE

Q34540403-467BEFA4-8B90-4E0F-A41A-DB3ABF9E6D95

Q34540403-79BD93B6-0F16-43ED-BFA8-62D55F4B41F6

Q34540403-880A79F0-B1D8-43B1-BDFB-EDB755D071C6

Q34540403-8E047EFC-8DD6-4173-B4AC-D5973BFA57E7

Q34540403-A5DB3368-6256-4CAA-95BA-5A7C9FDF96DA

Q34540403-B5D1AB94-06DE-4A5F-9D10-19768D7ABA12

Q34540403-D2887566-51B0-4A54-B149-FB145C81B3DE

P304

Q34540403-476F56D7-6289-4865-886E-938B0F5D3674

P31

Q34540403-5CAE1D9A-2AF1-4905-BCF3-E287337FB918

P356

Q34540403-AD3E0B9A-C444-46E3-910A-3BACAD41D773

P407

Q34540403-BBB2B989-EA41-4FCC-9725-F5B202E80637

P433

Q34540403-7C50D290-B8E2-4732-93BE-9B3D208239E2

P478

Q34540403-29A93403-0F7B-4058-ABC7-A136D73DF888

P50

Q34540403-0214384F-6D24-48FD-A0F3-82C068C6B86C

Q34540403-82253863-0E77-47D8-AD00-D17618F0D02B

Q34540403-D8C96AEC-90B3-4FF0-9D43-CDEFE44CADD6

P577

Q34540403-B09EBAC0-83DD-4DA7-93F3-ABB1A50F27A1

P698

Q34540403-097F8592-6FD8-42E2-8D52-9BF23202F6D1

P921

Q34540403-0BF3E58A-A51C-4C78-96B7-B0D9ED6ECE76

Q34540403-3ABA94C1-D599-4E16-8525-E693DA812BDE

Q34540403-D1620E55-E771-4EC1-A6C9-718D85DCE99B

P356

P1433

The New England Journal of Medicine

P1476

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

@en

P2093

Agostino Consoli

http://www.w3.org/2001/XMLSchema#string

Esteban Jódar

http://www.w3.org/2001/XMLSchema#string

Freddy G Eliaschewitz

http://www.w3.org/2001/XMLSchema#string

Ildiko Lingvay

http://www.w3.org/2001/XMLSchema#string

Jochen Seufert

http://www.w3.org/2001/XMLSchema#string

Jonas Pettersson

http://www.w3.org/2001/XMLSchema#string

Lawrence A Leiter

http://www.w3.org/2001/XMLSchema#string

Mark L Warren

http://www.w3.org/2001/XMLSchema#string

Oluf Hansen

http://www.w3.org/2001/XMLSchema#string

SUSTAIN-6 Investigators

http://www.w3.org/2001/XMLSchema#string

P304

1834-1844

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1607141

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Julio Rosenstock

P577

2016-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27633186

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

type-2 diabetes